Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Medical Officer | August 01, 2026 | August 04, 2026 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Chief Medical Officer | February 15, 2019 | February 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,541 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Tax withholding · Disposed 7,468 · Balance 205,541 F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026.
Whitehawk Therapeutics, Inc.
Report date February 15, 2019 · Filed February 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2029-02-15 | Direct | 125,000 |
Reported balance
After 2019-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 125,000 · Balance 125,000 F1: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2026 Filed Aug 4, 2026 20:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 7,468 | $9.69 | $72,364.92 |
DisclosureSEC source: 0001700659-26-000016 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,541 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 20:51 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,161 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0001700659-26-000014 · primarydocument.xml · derivative · entry 3 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,812 Underlying: Common Stock · 2,161 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 20:51 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,161 | $13.64 | $29,476.04 |
DisclosureSEC source: 0001700659-26-000014 · primarydocument.xml · nonDerivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,009 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 20:51 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,161 | $7.86 | $16,985.46 |
DisclosureSEC source: 0001700659-26-000014 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 00:08 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 36,725 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0001700659-26-000012 · primarydocument.xml · derivative · entry 4 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,973 Underlying: Common Stock · 36,725 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 00:08 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 36,725 | $12.86 | $472,283.50 |
DisclosureSEC source: 0001700659-26-000012 · primarydocument.xml · nonDerivative · entry 3 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,009 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 00:08 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 36,725 | $7.86 | $288,658.50 |
DisclosureSEC source: 0001700659-26-000012 · primarydocument.xml · nonDerivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 00:08 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 19,608 | $11.04 | $216,472.32 |
DisclosureSEC source: 0001700659-26-000012 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,009 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.00 to $11.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2026 Filed May 13, 2026 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,309 | $11.02 | $168,705.18 |
DisclosureSEC source: 0001700659-26-000010 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,617 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.00 to $11.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 22:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,124 | $10.35 | $53,033.40 |
DisclosureSEC source: 0001700659-26-000008 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,926 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:46 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 5,267 | $11.16 | $58,779.72 |
DisclosureSEC source: 0001700659-26-000006 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,050 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2026. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:44 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 35,402 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0001700659-26-000004 · primarydocument.xml · derivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,402 Underlying: Common Stock · 35,402 shares Expires 2036-01-06 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:44 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 65,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001700659-26-000004 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,317 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 18,247 | $14.40 | $262,756.80 |
DisclosureSEC source: 0001700659-26-000003 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,470 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023, January 2, 2024 and January 2, 2025. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. Read SEC document |
| February 01, 2025 Filed Apr 4, 2025 21:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 5,263 | $8.07 | $42,472.41 |
DisclosureSEC source: 0001562180-25-003009 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,717 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2025 Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 103,698 | $0.00 Strike: $7.86 | $0.00 |
DisclosureSEC source: 0001562180-25-000190 · primarydocument.xml · derivative · entry 3 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,698 Underlying: Common Stock · 103,698 shares Expires 2035-01-02 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 64,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000190 · primarydocument.xml · nonDerivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,980 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2026, January 1, 2027, January 1, 2028 and January 1, 2029 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:59 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 13,891 | $7.73 | $107,377.43 |
DisclosureSEC source: 0001562180-25-000190 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,687 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2025 based on the closing price of the issuer's common stock on December 31, 2024. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:41 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 58,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006017 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,578 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of February 1, 2025, August 1, 2025, February 1, 2026 and August 1, 2026 while the recipient provides continuous service to the Issuer. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 12,878 | $0.00 Strike: $22.25 | $0.00 |
DisclosureSEC source: 0001562180-24-002430 · primarydocument.xml · derivative · entry 3 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,277 Underlying: Common Stock · 12,878 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 44,155 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2024, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 12,878 | $28.36 | $365,220.08 |
DisclosureSEC source: 0001562180-24-002430 · primarydocument.xml · nonDerivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,192 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 12,878 | $22.25 | $286,535.50 |
DisclosureSEC source: 0001562180-24-002430 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 17,237 | $17.39 | $299,789.35 |
DisclosureSEC source: 0001562180-24-000252 · primarydocument.xml · nonDerivative · entry 3 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,192 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $17.05 to $17.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 50,875 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001562180-24-000252 · primarydocument.xml · derivative · entry 4 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,875 Underlying: Common Stock · 50,875 shares Expires 2034-01-02 F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 32,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000252 · primarydocument.xml · nonDerivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,429 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 10,385 | $17.95 | $186,410.75 |
DisclosureSEC source: 0001562180-24-000252 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,378 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the issuer's common stock on December 29, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 44,155 | $0.00 Strike: $22.25 | $0.00 |
DisclosureSEC source: 0001562180-23-000222 · primarydocument.xml · derivative · entry 4 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,155 Underlying: Common Stock · 44,155 shares Expires 2033-01-03 F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 90,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000222 · primarydocument.xml · nonDerivative · entry 3 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,763 F4 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,138 | $22.17 | $69,559.42 |
DisclosureSEC source: 0001562180-23-000222 · primarydocument.xml · nonDerivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,175 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.0000 to $22.3800. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 1,837 | $22.68 | $41,663.16 |
DisclosureSEC source: 0001562180-23-000222 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,313 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $34.31 | $0.00 |
DisclosureSEC source: 0001562180-22-000159 · primarydocument.xml · derivative · entry 4 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2032-01-03 F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 8,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000159 · primarydocument.xml · nonDerivative · entry 3 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,150 F3 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,598 | $33.75 | $53,932.50 |
DisclosureSEC source: 0001562180-22-000159 · primarydocument.xml · nonDerivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.72 to $33.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 1,152 | $32.70 | $37,670.40 |
DisclosureSEC source: 0001562180-22-000159 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,848 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:54 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 49,700 | $0.00 Strike: $44.97 | $0.00 |
DisclosureSEC source: 0001562180-21-000142 · primarydocument.xml · derivative · entry 2 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,700 Underlying: Common Stock · 49,700 shares Expires 2031-01-04 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 4, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:54 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000142 · primarydocument.xml · nonDerivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2022, January 1, 2023, January 1, 2024 and January 1, 2025 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 42,600 | $0.00 Strike: $38.99 | $0.00 |
DisclosureSEC source: 0001562180-20-000217 · primarydocument.xml · derivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,600 Underlying: Common Stock · 42,600 shares Expires 2030-01-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2021 while the optionee provides continuous service to the Issuer. Read SEC document |
| April 17, 2019 Filed Apr 19, 2019 20:14 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $54.72 | $0.00 |
DisclosureSEC source: 0001562180-19-002311 · primarydocument.xml · derivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2029-04-17 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following April 17, 2020 while the optionee provides continuous service to the Issuer. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:54 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-19-004277 · doc4.xml · derivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-02-15 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date date. Read SEC document |
| April 23, 2018 Filed Apr 26, 2018 00:23 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000899243-18-010746 · doc4.xml · derivative · entry 1 PAKOLA STEVE · CIK 0001700659 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-04-23 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the vesting start date and an additional 1/48th monthly thereafter until the fourth anniversary of the vesting start date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.